Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

被引：32

作者：

Diefenbach, Catherine S. ^{[1
]}

Hong, Fangxin ^{[2
]}

David, Kevin A. ^{[3
]}

Cohen, Jonathon ^{[4
]}

Robertson, Michael ^{[5
]}

Advani, Ranjana ^{[6
]}

Palmisiano, Neil D. ^{[7
]}

Ambinder, Richard F. ^{[8
]}

Kahl, Brad S. ^{[9
]}

Ansell, Stephen ^{[10
]}

机构：

[1] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA

[2] Dana Farber Canc Inst, ECOG ACRIN Biostatist Ctr, Boston, MA USA

[3] Northwestern Univ Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL USA

[4] Emory Univ, Atlanta, GA USA

[5] Indiana Univ Sch Med, Indianapolis, IN USA

[6] Stanford Canc Inst, Stanford, CA USA

[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA

[8] Johns Hopkins Med Inst, Div Hematol Malignancies, SKCCC, Baltimore, MD USA

[9] Washington Univ, St Louis, MO USA

[10] Mayo Clin, Rochester, MN USA

来源：

BLOOD | 2016年 / 128卷 / 22期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.V128.22.1106.1106

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1106

引用

页数：6

共 50 条

[21] 2-Year Follow-Up Results From the Phase 1-2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 10 - 11
[22] A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz, Pamela L.
Catalano, Paul J.
Nimeiri, Halla
Fisher, George A.
Longacre, Teri A.
Suarez, Carlos J.
Yao, James C.
Kulke, Matthew H.
Hendifar, Andrew Eugene
Shanks, James Christopher
Shah, Manisha H.
Zalupski, Mark
Schmulbach, Edmond L.
Reidy, Diane Lauren
Strosberg, Jonathan R.
O'Dwyer, Peter J.
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[23] A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Kunz, Pamela L.
Catalano, Paul J.
Nimeiri, Halla Sayed
Fisher, George A.
Longacre, Teri A.
Schrijver, Iris
Reidy, Diane Lauren
Strosberg, Jonathan R.
O'Dwyer, Peter J.
Benson, Al Bowen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)
Belani, Chandra P.
Dahlberg, Suzanne E.
Rudin, Charles M.
Fleisher, Martin
Chen, Helen X.
Takebe, Naoko
Velasco, Mario R.
Tester, William J.
Sturtz, Keren
Hann, Christine L.
Shanks, James C.
Monga, Manish
Ramalingam, Suresh S.
Schiller, Joan H.
CANCER, 2016, 122 (15) : 2371 - 2378
[25] A Phase 2 Trial of Dasatinib in Patients With Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kalinsky, Kevin
Lee, Sandra
Rubin, Krista M.
Lawrence, Donald P.
Iafrarte, Anthony J.
Borger, Darell R.
Margolin, Kim A.
Leitao, Mario M., Jr.
Tarhini, Ahmad A.
Koon, Henry B.
Pecora, Andrew L.
Jaslowski, Anthony J.
Cohen, Gary I.
Kuzel, Timothy M.
Lao, Christopher D.
Kirkwood, John M.
CANCER, 2017, 123 (14) : 2688 - 2697
[26] A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kalinsky, Kevin
Lee, Sandra J.
Rubin, Krista M.
Lawrence, Donald P.
Iafrate, A. John
Borger, Darrell R.
Margolin, Kim Allyson
Leitao, Mario M.
Koon, Henry B.
Tarhini, Ahmad A.
Pecora, Andrew
Cohen, Gary Irvin
Kuzel, Timothy
Kirkwood, John M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
Owonikoko, Taofeek K.
Dahlberg, Suzanne E.
Khan, Saad A.
Gerber, David E.
Dowell, Jonathan
Moss, Rebecca A.
Belani, Chandra P.
Hann, Christine L.
Aggarwal, Charu
Ramalingam, Suresh S.
LUNG CANCER, 2015, 89 (01) : 66 - 70
[28] Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)
Swinnen, Lode J.
O'Neill, Anne
Imus, Philip H.
Gujar, Sachin
Schiff, David
Kleinberg, Lawrence R.
Advani, Ranjana H.
Dunbar, Erin M.
Moore, Dennis
Grossman, Stuart A.
ONCOTARGET, 2018, 9 (01) : 766 - 773
[29] Phase 2 Study of Treatment Selection Based on Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E4203)
Meropol, Neal J.
Feng, Yang
Grem, Jean L.
Mulcahy, Mary F.
Catalano, Paul J.
Kauh, John S.
Hall, Michael J.
Saltzman, Joel N.
George, Thomas J., Jr.
Zangmeister, Jeffrey
Chiorean, Elena G.
Cheema, Puneet S.
O'Dwyer, Peter J.
Benson, Al B.
CANCER, 2018, 124 (04) : 688 - 697
[30] E2112: Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer: A Trial of the ECOG-ACRIN Cancer Research Group
Connolly, Roisin M.
Zhao, Fengmin
Miller, Kathy D.
Lee, Min-Jung
Piekarz, Richard L.
Smith, Karen L.
Brown-Glaberman, Ursa
Winn, Jennifer S.
Faller, Bryan A.
Onitilo, Adedayo A.
Burkard, Mark E.
Budd, George T.
Levine, Ellis G.
Royce, Melanie E.
Kaufman, Peter A.
Thomas, Alexandra
Trepel, Jane B.
Wolff, Antonio C.
Sparano, Joseph A.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 17 - 18

← 1 2 3 4 5 →